End-of-day quote
Mexican S.E.
18:00:00 2024-05-07 EDT
5-day change
1st Jan Change
17.36
MXN
+0.81%
+3.89%
+22.60%
Presenter SpeechUnknown Executive (Executives)Hello, everybody. I'm [ Damian ] [indiscernible]...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q1 2024 Earnings Call, Apr 25, 2024
04-25
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the First Quarter Ended March 31, 2024
04-24
CI
Genomma Lab Internacional, S.A.B. De C.V. Declares Cash Dividend
03-13
CI
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q4 2023 Earnings Call, Feb 22, 2024
02-22
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
02-21
CI
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Full Year Ended December 31, 2023
02-21
CI
Genomma Lab Internacional, S.A.B. De C.V. Announces Sixth Dividend Payment
12-13
CI
Procaps Group and Genomma Lab Announce Strategic Agreement to Manufacture and Market Softgel Products in Latin America
11-29
CI
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q3 2023 Earnings Call, Oct 26, 2023
23-10-26
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
23-10-24
CI
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q2 2023 Earnings Call, Jul 27, 2023
23-07-27
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-07-26
CI
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q1 2023 Earnings Call, Apr 27, 2023
23-04-27
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-04-27
CI
Transcript : Genomma Lab Internacional, S.A.B. de C.V. - Analyst/Investor Day
23-03-08
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q4 2022 Earnings Call, Feb 23, 2023
23-02-23
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022
23-02-22
CI
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Full Year Ended December 31, 2022
23-02-22
CI
IFC and Genomma Lab Sign Multi-Currency Long-Term Loan to Boost Access to OTC Medicines in Latin America and the Caribbean Region
23-01-09
CI
Genomma Lab Internacional, S.A.B. de C.V. Announces CEO Changes
22-11-28
CI
Genomma Lab Internacional, S.A.B. de C.V. Announces Management Changes
22-11-28
CI
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q3 2022 Earnings Call, Oct 27, 2022
22-10-27
Genomma Lab Internacional, S.A.B. De C.V. Cash Dividend
22-10-26
CI
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
22-10-26
CI
Tranche Update on Genomma Lab Internacional, S.A.B. de C.V. (BMV:LAB B)'s Equity Buyback Plan announced on March 20, 2013.
22-10-25
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Companyâs product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
More about the company
Last Close Price
17.36
MXN
Average target price
19.46
MXN
Spread / Average Target
+12.08%
Consensus
1st Jan change
Capi.
+22.60% 953M +32.95% 698B +26.51% 568B -4.97% 358B +18.83% 328B +3.54% 283B +15.70% 238B +6.68% 203B -9.08% 198B +6.70% 165B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1